GCP
BLTE

GSA Capital Partners’s Belite Bio BLTE Stock Holding History

GSA Capital Partners’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
1,645
+182
+12% +$30.6K 0.02% 1323
2025
Q4 		$234K Buy
+1,463
New +$173K 0.02% 1316

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GSA Capital Partners's BLTE Position: Q1 2026 in Review

GSA Capital Partners increased its Belite Bio (BLTE) stake by 12% in Q1 2026, buying an estimated $30.6K and bringing the position to 1,645 shares worth $262K. The position accounts for 0.02% of the portfolio, ranked #1323.

GSA Capital Partners first reported a position in BLTE in Q4 2025 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • GSA Capital Partners held 1,645 shares of Belite Bio worth $262K as of Q1 2026.
  • GSA Capital Partners bought 182 Belite Bio shares in Q1 2026, an estimated $30.6K.
  • Belite Bio made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1323 holding.
  • GSA Capital Partners first reported a position in Belite Bio in Q4 2025 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.